Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

On-admission Multifactorial Evaluation of Inflammation as Prognostic Marker of Death in Patients Diagnosed With Coronavirus Infectious Disease (COVID-19) Syndrome

NCT04371471 is registered in ClinicalTrials.gov with Groupe Hospitalier de la Rochelle Ré Aunis as lead sponsor.

NCT NCT04371471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04371471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
On-admission Multifactorial Evaluation of Inflammation as Prognostic Marker of Death in Patients Diagnosed With Coronavirus Infectious Disease (COVID-19) Syndrome
Lead sponsor
Groupe Hospitalier de la Rochelle Ré Aunis
Phase
Observational
Overall status
Completed
Start date
March 1, 2020
Completion date
April 30, 2020
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, sars-cov-2 acute respiratory disease